Published in Allergy on July 26, 2008
Mechanisms of Glucocorticoid Action in Chronic Rhinosinusitis. Allergy Asthma Immunol Res (2015) 0.78
Interleukin-1β regulates the expression of glucocorticoid receptor isoforms in nasal polyps in vitro via p38 MAPK and JNK signal transduction pathways. J Inflamm (Lond) (2015) 0.78
Molecular mechanisms of glucocorticoids action: implications for treatment of rhinosinusitis and nasal polyposis. Eur Arch Otorhinolaryngol (2010) 0.77
Relationship of glucocorticoid receptor expression in peripheral blood mononuclear cells and the cochlea of guinea pigs and effects of dexamethasone administration. PLoS One (2013) 0.75
Expression of the cysteinyl leukotriene 1 receptor and glucocorticoid receptor-β in nasal polyps. Eur Arch Otorhinolaryngol (2012) 0.75
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
The diagnosis and management of chronic cough. Eur Respir J (2004) 2.96
Practical guide to skin prick tests in allergy to aeroallergens. Allergy (2011) 2.51
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Chronic rhinosinusitis in Europe--an underestimated disease. A GA²LEN study. Allergy (2011) 2.13
EAACI position paper on rhinosinusitis and nasal polyps executive summary. Allergy (2005) 2.07
Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax (1991) 1.86
Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med (2001) 1.72
GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. Allergy (2009) 1.72
A survey of the burden of allergic rhinitis in Europe. Allergy (2007) 1.71
Nuclear factor-kappaB activity is down-regulated in nasal polyps from aspirin-sensitive asthmatics. Allergy (2003) 1.53
EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy (2007) 1.53
GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy (2009) 1.51
Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy (2000) 1.50
The effect of topical amphotericin B on inflammatory markers in patients with chronic rhinosinusitis: a multicenter randomized controlled study. Laryngoscope (2009) 1.46
Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review. Allergy (2010) 1.45
Osteitic bone in recalcitrant chronic rhinosinusitis. Rhinology (2011) 1.44
The effect of nasal steroid aqueous spray on nasal complaint scores and cellular infiltrates in the nasal mucosa of patients with nonallergic, noninfectious perennial rhinitis. J Allergy Clin Immunol (1997) 1.42
Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med (2000) 1.42
[On the translation of lobar and lobectomy into Spanish]. Arch Bronconeumol (2005) 1.40
Patients with chronic glucocorticoid treatment develop changes in muscle glycogen metabolism. J Neurol Sci (1993) 1.39
[Acute myopathy related to the administration of glucocorticoids and neuromuscular blockers]. Med Clin (Barc) (1994) 1.38
Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol (2001) 1.35
Mechanical ventilation in severe exacerbation of asthma. Study of 26 cases with six deaths. Eur J Respir Dis (1983) 1.26
Standard skin prick testing and sensitization to inhalant allergens across Europe--a survey from the GALEN network. Allergy (2005) 1.25
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy (2010) 1.24
Allergic rhinitis management pocket reference 2008. Allergy (2008) 1.23
GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'. Allergy (2009) 1.22
Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax (2003) 1.22
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy (2008) 1.20
Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax (2001) 1.14
Allergic rhinitis and its impact on otorhinolaryngology. Allergy (2006) 1.14
Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med (1999) 1.13
Rupatadine in allergic rhinitis and chronic urticaria. Allergy (2008) 1.13
Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy (2012) 1.13
Measurement of cell microrheology by magnetic twisting cytometry with frequency domain demodulation. J Appl Physiol (1985) (2001) 1.13
Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study. Am Rev Respir Dis (1990) 1.12
Cross-cultural adaptation and validation of the Dutch version of SWAL-QoL. Dysphagia (2008) 1.10
Genetic aspects of allergic rhinitis. J Investig Allergol Clin Immunol (2009) 1.10
Air pollution and allergens. J Investig Allergol Clin Immunol (2007) 1.09
Important research questions in allergy and related diseases: 3-chronic rhinosinusitis and nasal polyposis - a GALEN study. Allergy (2009) 1.08
Quality-assessment of disease-specific quality of life questionnaires for rhinitis and rhinosinusitis: a systematic review. Allergy (2007) 1.08
CT of pulmonary epithelioid hemangioendothelioma. J Comput Assist Tomogr (1994) 1.08
[Bronchial asthma and bronchial hyperreactivity: friends for ever]. Med Clin (Barc) (1996) 1.07
How epithelial cells detect danger: aiding the immune response. Allergy (2008) 1.06
Mucosal and systemic inflammatory changes in allergic rhinitis and asthma: a comparison between upper and lower airways. Clin Exp Allergy (2003) 1.05
Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy (2006) 1.05
GA2LEN skin test study III: minimum battery of test inhalent allergens needed in epidemiological studies in patients. Allergy (2009) 1.03
Stress and allergy. J Investig Allergol Clin Immunol (2009) 1.03
Lack of efficacy of long-term, low-dose azithromycin in chronic rhinosinusitis: a randomized controlled trial. Allergy (2011) 1.03
Local production and detection of (specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients. Eur Respir J (2000) 1.03
Effect of H1 antihistamines upon the central nervous system. J Investig Allergol Clin Immunol (2006) 1.01
Mechanisms of virus-induced asthma exacerbations: state-of-the-art. A GA2LEN and InterAirways document. Allergy (2007) 1.01
Chylothorax and tuberculosis. Thorax (1983) 1.01
Expression of the human glucocorticoid receptor alpha and beta isoforms in human respiratory epithelial cells and their regulation by dexamethasone. Am J Respir Cell Mol Biol (2001) 1.00
Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis. Thorax (2006) 0.99
Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy (2009) 0.99
Pulmonary involvement in primary biliary cirrhosis. Thorax (1981) 0.99
Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients--an observational, cross sectional study in four countries in Europe. J Med Econ (2011) 0.99
Geographical variation in the prevalence of sensitization to common aeroallergens in adults: the GA(2) LEN survey. Allergy (2014) 0.97
Validation of the Spanish version of the Asthma Control Test (ACT). J Asthma (2007) 0.97
Chronic rhinosinusitis and nasal polyps: the role of generic and specific questionnaires on assessing its impact on patient's quality of life. Allergy (2008) 0.97
Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol (2006) 0.97
Moderate local and systemic respiratory syncytial virus-specific T-cell responses upon mild or subclinical RSV infection. J Med Virol (2003) 0.96
Diffuse alveolar hemorrhage in allogeneic bone marrow transplantation. A postmortem study. Am J Respir Crit Care Med (1995) 0.96
Idiopathic rhinitis, the ongoing quest. Allergy (2005) 0.96
Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper. Int Arch Allergy Immunol (2012) 0.96
Substance P and neurokinin A in human nasal mucosa. Am J Respir Cell Mol Biol (1991) 0.95
Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments. Allergy (2005) 0.95
Lipid and protein metabolism in asthma. Effects of diet and corticosteroid therapy. Allergy (1999) 0.95
Vasoactive intestinal peptide in human nasal mucosa. J Clin Invest (1990) 0.95
Neuropeptide Y (NPY) in human nasal mucosa. Am J Respir Cell Mol Biol (1990) 0.95
Increase in IL-8, IL-10, IL-13, and RANTES mRNA levels (in situ hybridization) in the nasal mucosa after nasal allergen provocation. J Allergy Clin Immunol (1999) 0.94
Long terms results of Draf type III (modified endoscopic Lothrop) frontal sinus drainage procedure in 122 patients: a single centre experience. Rhinology (2011) 0.94
Allergen induced gene expression of airway epithelial cells shows a possible role for TNF-alpha. Allergy (2007) 0.93
The Sophia Anatomical Infant Nose-Throat (Saint) model: a valuable tool to study aerosol deposition in infants. J Aerosol Med (2001) 0.93
Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax (1994) 0.92
How many manoeuvres should be done to measure maximal inspiratory mouth pressure in patients with chronic airflow obstruction? Thorax (1989) 0.92
Nasal polyposis: a cellular-based approach to answering questions. Allergy (2007) 0.92
Glucocorticoid receptors in human airways. Allergy (2004) 0.92
Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression. Eur Respir J (2008) 0.92